tbuckley/cabot-search huggingface dataset:
Autologous Stem Cell Mobilization with Cytokines and in-Vivo Alemtuzumab in Patients with T-Cell Non-Hodgkin's Lymphoma (T-NHL).
Authors: De Padua Silva Leandro, Rima Saliba, Donna McCormick, Grace-Julia Okoroji, Amin Alousi, Paolo Anderlini, Stefan Ciurea, Chitra Hosing, Partow Kebriaei, Uday Popat, Muzaffar Qazilbash, Naoto Ueno, John McMannis, Richard Champlin, Barbara Pro, Issa F Khouri
Journal: Blood (2009)
Am80, a RARα Specific Synthetic Retinoid Induced a Strong Growth Inhibition in Hematologic Malignant Cells Including Myeloid and Lymphoid Cell Lines.
Authors: Shiro Jimi, Kota Mashima, Mitsukuni Sakabe, Emiko Ushijima, Junji Suzumiya, Shuji Hara, Kazuo Tamura
Journal: Blood (2005)
The Blood Monocyte - TNF - Endothelial Axis in Activation of Endothelial Tissue Factor in the Transgenic Sickle Mouse: Possible Relevance of Etanercept to Sickle Coagulopathy
Authors: Anna Solovey, Liming Milbauer Chang, Fuad Abdulla, Rahn Kollander, Paul H Marker, Robert Kelm, Gregory M Vercellotti, Robert P Hebbel
Journal: Blood (2011)
Heat Shock Protein 90 (HSP90) Inhibition by the Small Molecule 17-AAG Induces Cell Cycle Arrest and Apoptosis in Anaplastic Large Cell Lymphoma (ALCL) Irrespective of ALK Expression: Role of Akt, ERK and ALK Kinases in the Molecular Mechanisms of 17-AAG Anti-Tumor Activity.
Authors: Georgios V. Georgakis, Yang Li, George Z. Rassidakis, Felipe Samaniego, L. Jeffrey Medeiros, Anas Younes
Journal: Blood (2005)
Analysis of ROR1 Protein Expression in Human Cancer and Normal Tissues
Authors: Ashwini Balakrishnan, Tracy Goodpaster, Julie Randolph-Habecker, Benjamin G. Hoffstrom, Florencia G. Jalikis, Lisa K. Koch, Carolina Berger, Paula L. Kosasih, Anusha Rajan, Daniel Sommermeyer, Peggy L. Porter, Stanley R. Riddell
Journal: Clinical Cancer Research (2016)

Purpose: This study examines cell surface ROR1 expression in human tumors and normal tissues. ROR1 is considered a promising target for cancer therapy due to putative tumor-specific expression, and multiple groups are developing antibodies and/or chimeric antigen receptor-modified T cells to target ROR1. On-target, off-tumor toxicity is a challenge for most nonmutated tumor antigens; however, prior studies suggest that ROR1 is absent on most normal tissues.Experimental Design: Our studies show that published antibodies lack sensitivity to detect endogenous levels of cell surface ROR1 by immunohistochemistry (IHC) in formalin-fixed, paraffin-embedded tissues. We developed a ROR1-specific monoclonal antibody (mAb) targeting the carboxy-terminus of ROR1 and evaluated its specificity and sensitivity in IHC.Results: The 6D4 mAb is a sensitive and specific reagent to detect cell surface ROR1 by IHC. The data show that ROR1 is homogenously expressed on a subset of ovarian cancer, triple-negative breast cancer, and lung adenocarcinomas. Contrary to previous findings, we found ROR1 is expressed on several normal tissues, including parathyroid; pancreatic islets; and regions of the esophagus, stomach, and duodenum. The 6D4 mAb recognizes rhesus ROR1, and ROR1 expression was similar in human and macaque tissues, suggesting that the macaque is a suitable model to evaluate safety of ROR1-targeted therapies.Conclusions: ROR1 is a promising immunotherapeutic target in many epithelial tumors; however, high cell surface ROR1 expression in multiple normal tissues raises concerns for on-target off-tumor toxicities. Clinical translation of ROR1-targeted therapies warrants careful monitoring of toxicities to normal organs and may require strategies to ensure patient safety. Clin Cancer Res; 23(12); 3061-71. ©2016 AACR.
The Addition of Rituximab to First-Line Chemotherapy (R-CHOP) Results in Superior Response Rates, Time to Treatment Failure and Response Duration in Patients with Advanced Stage Mantle Cell Lymphoma: Long Term Results of a Randomized GLSG Trial
Authors: Eva Hoster, Michael Unterhalt, Bernhard Wörmann, Ulrich Dührsen, Bernd Metzner, Hartmut Eimermacher, Andreas Neubauer, Hannes Wandt, Hjalmar Steinhauer, Sonja Martin, Else Heidemann, Ali Aldaoud, Wolfgang Hiddemann, Martin Dreyling
Journal: Blood (2008)
Rituximab Followed by Involved Fields Radiotherapy (IF-RT) in Stage I-II Follicular Lymphoma (FL): Long Term Results,
Authors: Marco Ruella, Andrea Filippi, Anna DI Russo, Daniele Caracciolo, Paola Matteucci, Michele Magni, Massimo Di Nicola, Umberto Ricardi, Vittorio Montefusco, Guido Parvis, Corrado Tarella, Alessandro M. Gianni, Liliana Devizzi
Journal: Blood (2011)
A Novel Bcr-Abl Mediated Pro-Survival Pathway: Reduction of Releasable Calcium Levels in the Endoplasmic Reticulum Inhibits Calcium Dependent Apoptotic Signaling.
Authors: Susanne Vejda, Katarzyna Piwocka, Thomas G. Cotter, Gerald C. O’Sullivan, Sharon L. McKenna
Journal: Blood (2005)
A Multi-Center Prospective Randomized Study Comparing Ibritumomab Tiuxetan (Zevalin) and High-Dose BEAM Chemotherapy (Z-BEAM) Vs. BEAM Alone as the Conditioning Regimen Prior to Autologous Stem-Cell Transplantation In Patients with Aggressive Lymphoma; Possible Advantage for Z-BEAM In Low-Risk Patients
Authors: Avichai Shimoni, Irit Avivi, Jacob M. Rowe, Moshe Yeshurun, Itai Levi, Reuven Or, Paulina Patachenko, Abraham Avigdor, Tzila Zwas, Arnon Nagler
Journal: Blood (2010)
Clinical Comorbidity Measures and Predictive Scores in Ex Vivo T Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation
Authors: Robert Q. Le, Xin Tian, Natasha A Jain, Kit Lu, Sawa Ito, Debbie A Draper, Prathima Anandi, Christopher S. Hourigan, Neil Dunavin, John Barrett, Minoo Battiwalla
Journal: Blood (2014)
CXCR4 Antagonist BKT140 Synergizes with Rituximab, Targeting Non Hodgkin Lymphoma (NHL) In Vitro and In Vivo in a Xenograft Model with Bone Marrow Involvement
Authors: Katia Beider, Elena Ribakovsky, Michal Abraham, Hanna Wald, Orly Eizenberg, Abraham Avigdor, Amnon Peled, Arnon Nagler
Journal: Blood (2011)
Towards Clinically Feasible Co-Stimulatory Blockade for Tolerance Induction: Transient Treatment with CTLA4-Ig, Anti-CD48 and FTY720 Enables Durable Engraftment of T Cell Depleted BM Allografts Following Non-Myeloablative Conditioning.
Authors: Esther Bachar-Lustig, Dalit Tchorsh-Yutsis, Eran Ophir, Yael Zlotnikov Klionsky, Noga Or-Geva, Yair Reisner
Journal: Blood (2010)
Redox reactivity predicts metastatic potential of human breast cells via protein kinase Cα
Authors: Susan A. Rotenberg, Wenju Feng, Wei Cheng, Corinne A. Michels, Michael V. Mirkin
Journal: Cancer Research (2004)

Proc Amer Assoc Cancer Res, Volume 45, 2004

5021 

BP1 is a member of the homeobox gene superfamily of transcription factors that are essential for early development. Our recent studies, however, have revealed that the BP1 gene is activated in the tumor cells of 80% of breast infiltrating ductal carcinoma (IDC), whereas it is silent in the adjacent normal cells and in a vast majority of normal matched controls (Fu et al. Breast Cancer Research 5:82-87, 2003). This study attempted to confirm those results using an immunohistochemical approach. BP1 levels were examined during tumor progression to determine whether the expression of the BP1 protein increases with the advance of hypothesized stages of tumor progression (normal→hyperplasia→in situ→invasive and metastasis), and whether cells among cancer subtypes share a similar pattern of BP1 expression. Paraffin sections of reduction mammoplasties (n=34), regular intraductal hyperplasia (IDH, n=40), and multiple histological varieties of ductal carcinoma in situ (DCIS) and IDC (n=200) were immunostained with a BP1 polyclonal antibody utilizing the ABC method. The frequency and pattern of BP1 immunostaining among cases and among cells were semi-quantitatively compared. Greater than 95% of the cells in normal reduction mammoplasty controls were devoid of distinct BP1 immunostaining, whereas BP1 immunostaining was detected in approximately 33% of IDH, 50% of DCIS, and 80% of IDC cases. The number of BP1 immunoreactive cells per sample varied substantially between IDH and DCIS. In IDH and DCIS, about 5% to 30% of the cells were immunoreactive, respectively, whereas a vast majority of the IDC cells showed distinct BP1 immunostaining. In tissues containing simultaneous normal, IDH, DCIS, and IDC, the invasive cells consistently displayed the highest intensity of BP1 staining, followed by in situ tumor cells. The overall pattern of BP1 expression among the different breast cancer subtypes was similar, except that distinct BP1 immunostaining was preferentially detected in a subset of myoepithelial cells in pregnancy-associated cancers. Together, these findings suggest that BP1 expression is closely associated with tumor progression.
Compendium of Karyotypic Abnormalities and Their Clinical Implications in Hyperdiploid Multiple Myeloma (H-MM).
Authors: Wee-Joo Chng, Scott Van Wier, Gregory Ahmann, Rafael Santana-Davila, Syed Jalal, Rhett Ketterling, Peter Leif Bergsagel, Marta Chesi, Mike Trendle, Martin Oken, Emily Blood, Kim Henderson, Robert Kyle, Morie Gertz, Martha Lacy, Angela Dispenzieri, Philip Greipp, Rafael Fonseca
Journal: Blood (2005)
A Case Where Switching the End Points for Clinical Trial Interpretation Might Be the Right Choice
Authors: Francesco Perrone, Massimo Di Maio, Lucia Del Mastro
Journal: JAMA Oncology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
FRI0494 Arthritis Post Chikungunya Fever: Clinical Profile of A Population of Patients in A Secondary Care Hospital
Authors: J. Losanto, A. Ojeda, F. Giménez
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Chikungunya fever is a viral disease caused by an alphavirus that belongs to the Togaviridae family, it is transmitted by mosquitoes of the gender Aedes. Acute symthomps manifests with high fever, skin rash and arthritis. A high percentage of patients can develop severe and disabling poliarthritis. In 2015 there was an outbreak of this desease in outskirts of the capital city, presenting several cases of arthritis of chikungunya fever <h3>Methods</h3> Retrospective, descriptive and cross-sectional study of patients who consulted in a secondary care hospital from Villa Elisa city, for persistent joint pain after chikungunya9s fever in the period from March to June of 2015. It was conducted describing the characteristics of clinical state, demographic, treatment and patient outcomes. Statistical analysis was performed with SPSS19.0 program. The qualitative variables were expressed as frequencies and percentages, quantitative variables in mean. <h3>Results</h3> 26 patients from the capital city and outskirts were included, 92% of females with the average age of 47.2 years old. The average duration of acute fever was 2.86 days. The predominant symptoms were headache (76.9%), joint pain (92.3%). 92.3% had skin rash in the acute stage, with an average duration of 4.5 days. The joint symptoms began after an average of 14 days after the fever started. The metacarpal phalangeal and interphalangeal joints were affected in 73% of patients, the radiocarpal joints and knees in 76.9%, shoulders in the 50% and feet in 92.3%. All patients were treated with NSAIDs and 20/26 patients (76.9%) was added prednisone at a dose of 40 mg/day with fast and gradual tapering treatment in two weeks, with 92.3% with partial or total relief of symptoms. In 2 patients (7.6%) was decided to add methotrexate for recurrence of the arthritis, whit the decrease of corticosteroids doses. <h3>Conclusions</h3> Chikungunya9s fever is a major public health problem with increasing cases reports in urban areas, especially for its ability to generate medium and long-term rheumatological complications. It is important to mention the high frequency of hand and feet involvement, leading to several degrees of disability as well impairments, even laboral absenteeism because of the intensity of the pain. Even though the follow-up period is short, it is highlighted the excellent response to this treatment with short time of corticosteroids, although it is needed a longer follow up to define the appropriate treatment according to the evolution and outcome of cases, and with this develop protocols for such cases. <h3>Disclosure of Interest</h3> None declared
Harold E. Lebovitz, MD: Legendary Diabetologist
Authors: Jay S. Skyler
Journal: Diabetes Care (2016)

Harold (Hal) Lebovitz turned 85 years old in October 2016. You wouldn’t know it from his travel schedule. He seems to go to India, or somewhere equally far, at least once a month. Despite long travels, he always shows up looking very perky and full of energy. In Harold’s case, some people will drive as much as 500 miles to attend his presentations, and as one physician commented, “Oh, yes, Harold Lebovitz is the greatest. I would go any distance to hear him speak.” And, in speaking, he has always adjusted his presentation to fit exactly to the time allocated without apparently looking at his watch. His array of topics spans all of diabetes and is always quite up to date.

Harold Emil Lebovitz was born in Pittsburgh, PA, on 13 October 1931 to David (Dave) and Frieda Pachman Lebovitz. Harold’s father, Dave, had wanted to be a physician, but his parents told Dave he could never support a family as a physician, so he became a pharmacist. Dave opened Lawrenceville Drugs in Pittsburgh. The family lived above the store and Harold and his older brother, Al, as teenagers and while in college, worked there as soda jerks and helped fill prescriptions. All three of the brothers became physicians: Al, now deceased, was a psychiatrist; Harold is an endocrinologist; and Philip, the youngest, is a cardiologist. Dave continued to work actively as a pharmacist, even after selling his store and moving to Florida, only retiring at age 86.



Harold Lebovitz at college graduation





Harold as a young faculty member



Harold received his undergraduate and medical degrees, in 1952 and 1956, respectively, from the University of Pittsburgh. During his senior year of medical school, he was a Lederle Research Student Fellow in Pathology. He also served as president of Alpha Omega …
Prognostic Value of FDG-PET in Lymphoma Patients Undergoing Autologous Stem Cell Transplantation.
Authors: Jakub Svoboda, Rebecca Elstrom, Elise A. Chong, Charalambos Andreadis, Arnold Berkowitz, Selina M. Luger, David L. Porter, Sunita Nasta, Lisa H. Downs, Donald L. Siegel, Eli Glatstein, Abass Alavi, Edward A. Stadtmauer, Stephen J. Schuster
Journal: Blood (2005)
PTU-065 Four-Way Comparison of Elisa Methods Available for the Measurement of Infliximab and Anti-Infliximab Antibody in IBD Patients
Authors: N Unsworth, MA Samaan, B Warner, Z Arkir, PM Irving
Journal: Gut (2016)

<h3>Introduction</h3> Commercial assays are now widely available and in routine use for the therapeutic drug monitoring of Infliximab (IFX) and anti-Infliximab antibody (ADAb). Although results generated using these assays are used to guide clinical decision making, there is no standardisation and data assessing the comparability between these assays is lacking. <h3>Methods</h3> A prospective evaluation of IFX drug levels and ADAb was performed using our standard ELISA assay; LISA TRACKER (Theradiag) and also Promonitor (Proteomika), IDKmonitor (Immundiagnostik) and RIDASCREEN IFX (R-Biopharm AG / KU Leuven) ELISA assays. 105 samples from 102 IBD patients were analysed for IFX, free ADAb (LT/PRO) and total ADAb (ID) automated on eRobot and Grifols Triturus analysers. LT, PRO and RS kits were provided at no cost.Method comparisons were performed using difference plots and Passing Bablok analysis. <h3>Results</h3> A summary of IFX drug level comparison data is shown in the image below. The distribution of bias between methods was variable (-6.7% to +87.8%) with PRO and ID showing scattered, bimodal distributions of %bias. A consistent, proportional relationship was observed between LT and RS results. Free ADAb were detected in 4/105 (3.8%) samples using LT and 3/105 using PRO. All patients with detectable free ADAb had undetectable IFX drug levels. Conversely, total ADAb were detected in 23/105 (21.9%) samples but IFX drug levels were sub-therapeutic (&lt;1.0 ug/mL) in only 6/23 (26.1%) of these and therapeutic (&gt;2.0 ug/mL) in the majority of cases (13/23). <h3>Conclusion</h3> These results show that there is significant variation in IFX drug levels obtained when using different CE marked ELISA assays and as such, results are not directly comparable. Although the clinical utility of measuring total ADAb is yet to be established, a significant proportion of patients tested will be positive for total ADAb irrespective of therapeutic IFX drug levels. In the absence of assay standardisation and external quality assurance, laboratory providers and clinicians should ensure that assays currently in routine use are fit for purpose. <h3>Disclosure of Interest</h3> None Declared
Results of the phase Ib portion of a phase I/II trial of the indoleamine 2,3-dioxygenase pathway (IDO) inhibitor indoximod plus gemcitabine/nab-paclitaxel for the treatment of metastatic pancreatic cancer.
Authors: Nathan Bahary, Ignacio Garrido-Laguna, Andrea Wang-Gillam, Asha Nyak-Kapoor, Eugene Kennedy, Nicholas N. Vahanian, Charles J. Link
Journal: Journal of Clinical Oncology (2016)

452 Background: IDO is a tryptophan-catabolizing enzyme that plays a key role in the normal regulation of peripheral immune tolerance. Tumors also employ this mechanism to induce a state of immunosuppression. In cancer, IDO mediates an acquired immune tolerance towards tumors, allowing evasion of immune mediated destruction. Indoximod is a broad IDO pathway inhibitor, as it has been shown to potentially interfere with multiple targets within the IDO pathway. Pre-clinical models have demonstrated synergy between indoximod and chemotherapy. The combination of gemcitabine (Gem) and nab-paclitaxel (Nab) is a current SOC for first line treatment of metastatic pancreas cancer. This trial is designed to determine the potential for benefit of combination therapy with indoximod and Gem / Nab for to patients with metastatic pancreatic cancer. Methods: Indoximod was escalated (600mg/1000mg/1200mg PO twice daily continuous dosing) in combination with Gem / Nab (1000mg/m 2 / 125mg/m 2 q week x 3 per 4 week cycle) in a 3+3 design. Patients were first line metastatic pancreatic cancer or minimum 6 months from adjuvant chemo and / or radiation following previous resection. Treatment continues until progression or toxicity. Primary endpoints for Phase 1 include safety, toxicity, and determination of a Phase 2 dose. The prospective collection of tumor samples for exploration of biomarkers is built into the trial. Results: 15 patients were required to successfully dose escalate the Phase 1 study to 1200 mg twice daily. Two patients were replaced in the lowest dose cohort after rapid deterioration due to underlying disease during the regimen limiting toxicity (RLT) window. One RLT was observed during the study (ascites Grade 3) at the highest dose cohort. The most common AE’s (all Grade 1 or 2) occurring in ≥ 4 subjects, regardless of attribution, were nausea, fatigue, peripheral edema, peripheral neuropathy, alopecia. Conclusions: Indoximod and Gem / Nab were well tolerated in a clinical trial setting. The Phase 2 dose was set at 1200 mg twice daily and Phase 2 enrollment (target 80 patients) is ongoing. Updated results will be presented. Clinical trial information: NCT02077881.
Abstract A45: Osteoblastic niche supports the growth of quiescent multiple myeloma cells.
Authors: Zheng Chen, Robert Z. Orlowski, Michael Wang, Larry Kwak, Nami McCarty
Journal: Clinical Cancer Research (2015)

Abstract The heterogeneity of multiple myeloma (MM) contributes to variable responses to therapy. In this study, we aim to correlate the heterogeneity of MM to the presence of quiescent cells using the PKH26 dye. We tracked the rare quiescent cells in different niches of the bone marrow by allowing the cells to cycle in vivo. Surprisingly, quiescent PKH+ MM cells prefer to reside within the osteoblastic niches of the bone marrow (PKH+/OS) rather than the vascular niches or the spleen. These cells (PKH+/OS) displayed enhanced stem-like properties by forming colonies in semi-solid medium. PKH+ cells were highly tumorigenic, as compared to PKH- cells, and were resistant to a variety of drugs. However, the levels of drug resistance were somewhat similar regardless of where the PKH+ cells were isolated. Our data indicate that osteoblastic niches support the growth of quiescent PKH+ cells and allow them to have stem-like functions. Citation Format: Zheng Chen, Robert Z. Orlowski, Michael Wang, Larry Kwak, Nami McCarty. Osteoblastic niche supports the growth of quiescent multiple myeloma cells. [abstract]. In: Proceedings of the AACR Special Conference on Hematologic Malignancies: Translating Discoveries to Novel Therapies; Sep 20-23, 2014; Philadelphia, PA. Philadelphia (PA): AACR; Clin Cancer Res 2015;21(17 Suppl):Abstract nr A45.
Different Expression of FcgammaRIIb in Chronic Lymphocytic Leukemia and Human Normal B Lymphocytes
Authors: Carol Moreno, Rajendra Damle, Sonia Jansa, Gerardo Ferrer, Pau Abrisqueta, Aina Pons, Marta Aymerich, Ezio Bonvini, Joshua Trott, Emili Montserrat, Nicholas Chiorazzi
Journal: Blood (2008)
Clinical Significance of Homozygous D13S319 Deletion in B-Cell Chronic Lymphocytic Leukemia (B-CLL).
Authors: Stephanie Fink, Susan Geyer, Tait Shanafelt, Stephanie Smoley, Sarah Paternoster, Karin Giordano, Renee Tschumper, Diane Jelinkek, Nancy Bone, Brian Kabat, Timothy Call, Robert Phyliky, Neil Kay, Gordon Dewald
Journal: Blood (2004)
Randomized Comparison of 4-Times-Daily Versus Once-Daily Intravenous Busulfan in a Conditioning Therapy for Hematopoietic Cell Transplantation (HCT).
Authors: Seong-Gil Ryu, Je-Hwan Lee, Seong-Jun Choi, Jung-Hee Lee, Young-Shin Lee, Miee Seol, Eun-Hye Hur, Soo Han Lee, Kyun Seop Bae, Gyu Jeong Noh, Moo-Song Lee, SungCheol Yun, Sang Beom Han, Kyoo Hyung Lee
Journal: Blood (2006)
The Novel Proteasome Inhibitor 5-Amino-8-Hydroxyquinole (5AHQ) Overcomes Bortezomib Resistance in Malignant Hematological Cell Line Models Harboring Mutations in the PSMB5 Gene.
Authors: Niels E Franke, Johan van Meerloo, Linda Slot, Xiaoming Li, Tabitha E Wood, Katarina Vojtekova, Sue Ellen Verbrugge, Gertjan Kaspers, Robert A. Batey, Aaron D. Schimmer, Gerrit Jansen, Jacqueline Cloos
Journal: Blood (2009)